Reports Q2 revenue $178.494M, consensus $188.65M. “We are incredibly proud of the recent FDA approval of EMPAVELI in C3G and primary IC-MPGN and are now focused on bringing this transformational therapy to patients. With two C3-targeting medicines approved across four serious diseases, we have further cemented our position as a leader in complement,” said Cedric Francois, M.D., Ph.D., chief executive officer at Apellis (APLS). “On top of our regulatory success, we were encouraged to see SYFOVRE’s continued market leadership in GA.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target raised to $22 from $20 at Scotiabank
- Buy Rating for Apellis Pharmaceuticals Driven by FDA Approval and Promising Financial Projections for Empaveli
- Positive Outlook for Apellis Pharmaceuticals Following Empaveli Approval
- Cautious Optimism for Apellis Pharmaceuticals Amid Empaveli Approval and Market Challenges
- Apellis price target raised to $46 from $41 at Citi